What impact does bipolar disorder staging have on the use of pharmacotherapy?
Expert Opin Pharmacother. 2021 Apr 16:1-4. doi: 10.1080/14656566.2021.1915988. Online ahead of print.NO ABSTRACTPMID:33858288 | DOI:10.1080/14656566.2021.1915988 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - April 16, 2021 Category: Drugs & Pharmacology Authors: Jairo Vin ícius Pinto M árcia Kauer-Sant'Anna Lakshmi N Yatham Source Type: research

An up-to-date evaluation of abiraterone for the treatment of prostate cancer
Expert Opin Pharmacother. 2021 Apr 15. doi: 10.1080/14656566.2021.1915287. Online ahead of print.ABSTRACTIntroduction: Abiraterone acetate, an oral 17-alpha-hydroxylase inhibitor, effectively prevents the synthesis of androgens from steroid precursors. Abiraterone has become a standard of care in patients with metastatic prostate cancer due to its efficacy in both castrate-sensitive and castrate-resistant disease when given in combination with androgen deprivation therapy (ADT). Abiraterone may have a role in additional aspects of prostate cancer treatment in the future.Areas covered: The present article focuses on the dev...
Source: Expert Opinion on Pharmacotherapy - April 15, 2021 Category: Drugs & Pharmacology Authors: Jason Shpilsky Julia Stevens Glenn Bubley Source Type: research

What place does ceftolozane/tazobactam have in the treatment of complicated urinary-tract infections?
Expert Opin Pharmacother. 2021 Apr 14. doi: 10.1080/14656566.2021.1915286. Online ahead of print.NO ABSTRACTPMID:33849371 | DOI:10.1080/14656566.2021.1915286 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - April 14, 2021 Category: Drugs & Pharmacology Authors: Rita Murri Emilio Sacco Source Type: research

Aripiprazole IM depot as an option for the treatment of bipolar disorder
Expert Opin Pharmacother. 2021 Apr 13:1-10. doi: 10.1080/14656566.2021.1910236. Online ahead of print.ABSTRACTIntroduction: Long-acting injectable (LAI) antipsychotic drugs are developed to reduce daily intake need and to overcome treatment non-adherence. Aripiprazole IM depot refers to two long-acting aripiprazole formulations, once monthly monohydrate (AOM) and aripiprazole lauroxil. AOM has been approved for schizophrenia since 2012 and for bipolar disorder since 2017. Aripiprazole lauroxil is approved for schizophrenia, not for bipolar disorder.Areas covered: To assess the effect of AOM in bipolar disorder, the authors...
Source: Expert Opinion on Pharmacotherapy - April 13, 2021 Category: Drugs & Pharmacology Authors: Georgios D Kotzalidis Chiara Rapinesi Chiara Chetoni Sergio De Filippis Source Type: research

Are 5-HT < sub > 1 < /sub > receptor agonists effective anti-migraine drugs?
Expert Opin Pharmacother. 2021 Apr 12:1-5. doi: 10.1080/14656566.2021.1910235. Online ahead of print.NO ABSTRACTPMID:33843394 | DOI:10.1080/14656566.2021.1910235 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - April 12, 2021 Category: Drugs & Pharmacology Authors: Masaru Tanaka N óra Török L ászló Vécsei Source Type: research

Real-world safety and efficacy of twice-daily budesonide 2-mg foam in patients with ulcerative colitis: interim analysis of post-marketing surveillance
Expert Opin Pharmacother. 2021 Apr 9:1-7. doi: 10.1080/14656566.2021.1905796. Online ahead of print.ABSTRACTBackground: Budesonide foam 2 mg twice daily induced complete mucosal healing in patients with mild-to-moderate ulcerative colitis (UC) in a phase 3 study. Post-marketing surveillance is underway to assess the real-world outcomes in UC patients.Research design and methods: The authors performed an interim analysis of post-marketing surveillance in 182 patients with mild-to-moderate UC who received 2 mg budesonide foam rectally.Results: Budesonide foam was prescribed twice daily to 76.4% of patients for 7.6 ± 3...
Source: Expert Opinion on Pharmacotherapy - April 9, 2021 Category: Drugs & Pharmacology Authors: Teppei Omori Masayuki Saruta Akira Nagaki Yuki Arai Akira Ohta Kiyotoshi Kuramoto Yasuo Suzuki Source Type: research

Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer
Expert Opin Pharmacother. 2021 Apr 7:1-8. doi: 10.1080/14656566.2021.1912015. Online ahead of print.ABSTRACTINTRODUCTION: Metastatic prostate cancer is a heterogeneous disease characterized by clinical and genomic heterogeneity. Many prostate cancers harbor mutations causing DNA repair deficiency, specifically homologous recombination deficiency, sensitizing to drugs that inhibit poly ADP-ribose polymerase (PARP). PARP is an enzyme that is involved in single-stranded DNA repair and is the target of newly approved treatments for metastatic prostate cancer.AREAS COVERED: Here, the authors' review the clinical trials leading ...
Source: Expert Opinion on Pharmacotherapy - April 8, 2021 Category: Drugs & Pharmacology Authors: Benjamin L Maughan Emmanuel S Antonarakis Source Type: research

Escalating Antimicrobial Resistance Among Enterobacteriaceae: Focus on Carbapenemases
Expert Opin Pharmacother. 2021 Apr 6. doi: 10.1080/14656566.2021.1904891. Online ahead of print.NO ABSTRACTPMID:33823714 | DOI:10.1080/14656566.2021.1904891 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - April 7, 2021 Category: Drugs & Pharmacology Authors: Joseph P Lynch Nina M Clark George G Zhanel Source Type: research

Managing dyslipidemia in patients with type 2 diabetes
Expert Opin Pharmacother. 2021 Apr 6. doi: 10.1080/14656566.2021.1912734. Online ahead of print.ABSTRACTINTRODUCTION: Type 2 diabetes mellitus (T2DM) is associated with increased risk for atherosclerotic cardiovascular disease (ASCVD) which is partly related to the atherogenic dyslipidemia with raised triglycerides, reduced high-density lipoprotein cholesterol levels and accompanying lipid changes. Treatment of this dyslipidemia is regarded as a priority to reduce the ASCVD risk in T2DM.AREAS COVERED: In this article, the authors review the relevant studies and guidelines from the publications related to this area.EXPERT O...
Source: Expert Opinion on Pharmacotherapy - April 7, 2021 Category: Drugs & Pharmacology Authors: Brian Tomlinson Nivritti Gajanan Patil Manson Fok Christopher Wai Kei Lam Source Type: research

Careful use to minimize adverse events of oral antidiabetic medications in the elderly
This article discusses some characteristics of older patients that could increase the risk of adverse events, with a focus on hypoglycemia. It describes the most frequent and/or severe complications reported in the elderly in both randomized controlled trials and observational studies with metformin, sulfonylureas, meglitinides, alpha-glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase-4 inhibitors (gliptins) and sodium-glucose cotransporter type 2 inhibitors (gliflozins).EXPERT OPINION: : Old patients may present comorbidities (renal impairment, vascular disease, heart failure, risk of dehydration, osteoporos...
Source: Expert Opinion on Pharmacotherapy - April 7, 2021 Category: Drugs & Pharmacology Authors: Andr é J Scheen Source Type: research

An overview of pharmacotherapy for cerebral vasospasm and delayed cerebral ischemia after subarachnoid hemorrhage
Expert Opin Pharmacother. 2021 Apr 6. doi: 10.1080/14656566.2021.1912013. Online ahead of print.ABSTRACTINTRODUCTION: Survival from aneurysmal subarachnoid hemorrhage has increased in the past few decades. However, functional outcome after subarachnoid hemorrhage is still suboptimal. Delayed cerebral ischemia (DCI) is one of the major causes of morbidity.AREAS COVERED: Mechanisms underlying vasospasm and DCI after aneurysmal subarachnoid hemorrhage and pharmacological treatment are summarized in this review.EXPERT OPINION: Oral nimodine, an L-type dihydropyridine calcium channel blocker, is the only FDA-approved drug for t...
Source: Expert Opinion on Pharmacotherapy - April 7, 2021 Category: Drugs & Pharmacology Authors: Tatsuya Maruhashi Yukihito Higashi Source Type: research

Considerations for single- versus multiple-drug pharmacotherapy in the management of painful diabetic neuropathy
Expert Opin Pharmacother. 2021 Apr 5:1-14. doi: 10.1080/14656566.2021.1909570. Online ahead of print.ABSTRACTINTRODUCTION: The efficacy of monotherapy to reduce pain from diabetic peripheral neuropathy (DPN) is frequently not satisfactory and guidelines do not provide unanimous treatment options. In this context, multiple drug pharmacotherapy may provide benefit.AREAS COVERED: The aim of the present review is to describe the clinical trials addressing the pharmacotherapy of painful DPN. Studies discussing efficacy and tolerability of pharmacological agents that were assessed in monotherapy and in combination treatment are ...
Source: Expert Opinion on Pharmacotherapy - April 5, 2021 Category: Drugs & Pharmacology Authors: Kalliopi Pafili Nikolaos Papanas Source Type: research

Choosing the appropriate pharmacotherapy for hepatitis B during pregnancy: what are the considerations?
Expert Opin Pharmacother. 2021 Apr 2:1-4. doi: 10.1080/14656566.2021.1909571. Online ahead of print.NO ABSTRACTPMID:33797300 | DOI:10.1080/14656566.2021.1909571 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - April 2, 2021 Category: Drugs & Pharmacology Authors: Alberto Enrico Maraolo Source Type: research

New and emerging pharmacological treatment options for acromegaly
Expert Opin Pharmacother. 2021 Mar 30. doi: 10.1080/14656566.2021.1908998. Online ahead of print.ABSTRACTINTRODUCTION: Transsphenoidal surgery is the first-line treatment for acromegaly, but even in referral centers, approximately 50% of patients are not cured, and adjuvant pharmacological treatment is necessary. Widely used therapies encompass different drug classes, such as injectable somatostatin receptor ligands (SRLs), oral dopamine agonists and injectable growth hormone receptor antagonists, but approximately 40% of patients still have disease activity in real-life practice. Therefore, there is a need for new medical...
Source: Expert Opinion on Pharmacotherapy - March 30, 2021 Category: Drugs & Pharmacology Authors: Ximene Antunes Leandro Kasuki M ônica R Gadelha Source Type: research

Finerenone - are we there yet with a non-steroidal mineralocorticoid receptor antagonist for the treatment of diabetic chronic kidney disease?
Expert Opin Pharmacother. 2021 Mar 25:1-4. doi: 10.1080/14656566.2021.1904892. Online ahead of print.ABSTRACTIntroduction: Chronic kidney disease occurs in 40% of subjects with diabetes and increases the risk of cardiovascular death three-fold, compared to having diabetes alone. The non-steroidal mineralocorticoid receptor antagonist finerenone protects against chronic kidney disease in animal models.Areas covered: This evaluation is of a phase 3 trial of finerenone; Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD). In FIDELIO-DKD, finerenone reduced the primary composi...
Source: Expert Opinion on Pharmacotherapy - March 25, 2021 Category: Drugs & Pharmacology Authors: Sheila A Doggrell Source Type: research

Issues in Antibiotic Therapy for Hospital-Acquired and Ventilator-Associated Pneumonia: Emerging Concepts to Improve Outcomes
Expert Opin Pharmacother. 2021 Mar 25. doi: 10.1080/14656566.2021.1908997. Online ahead of print.ABSTRACTIntroductionVentilator-associated pneumonia (VAP) and hospital-acquired pneumonia (HAP) result in significant morbidity and mortality. The emergence of multi-drug resistant organisms has complicated the matter, as many of these pathogens now represent key causes of VAP and HAP. While a number of new medications have been approved, a comprehensive appreciation of pharmacokinetic and pharmacodynamic principles, which, are often neglected, is key to effective treatment.Areas coveredThe authors discuss the central pharmacok...
Source: Expert Opinion on Pharmacotherapy - March 25, 2021 Category: Drugs & Pharmacology Authors: Syed Nazeer Mahmood Andrew F Shorr Source Type: research

Finerenone - are we there yet with a non-steroidal mineralocorticoid receptor antagonist for the treatment of diabetic chronic kidney disease?
Expert Opin Pharmacother. 2021 Mar 25:1-4. doi: 10.1080/14656566.2021.1904892. Online ahead of print.ABSTRACTIntroduction: Chronic kidney disease occurs in 40% of subjects with diabetes and increases the risk of cardiovascular death three-fold, compared to having diabetes alone. The non-steroidal mineralocorticoid receptor antagonist finerenone protects against chronic kidney disease in animal models.Areas covered: This evaluation is of a phase 3 trial of finerenone; Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD). In FIDELIO-DKD, finerenone reduced the primary composi...
Source: Expert Opinion on Pharmacotherapy - March 25, 2021 Category: Drugs & Pharmacology Authors: Sheila A Doggrell Source Type: research

Issues in Antibiotic Therapy for Hospital-Acquired and Ventilator-Associated Pneumonia: Emerging Concepts to Improve Outcomes
Expert Opin Pharmacother. 2021 Mar 25. doi: 10.1080/14656566.2021.1908997. Online ahead of print.ABSTRACTIntroductionVentilator-associated pneumonia (VAP) and hospital-acquired pneumonia (HAP) result in significant morbidity and mortality. The emergence of multi-drug resistant organisms has complicated the matter, as many of these pathogens now represent key causes of VAP and HAP. While a number of new medications have been approved, a comprehensive appreciation of pharmacokinetic and pharmacodynamic principles, which, are often neglected, is key to effective treatment.Areas coveredThe authors discuss the central pharmacok...
Source: Expert Opinion on Pharmacotherapy - March 25, 2021 Category: Drugs & Pharmacology Authors: Syed Nazeer Mahmood Andrew F Shorr Source Type: research

Finerenone - are we there yet with a non-steroidal mineralocorticoid receptor antagonist for the treatment of diabetic chronic kidney disease?
Expert Opin Pharmacother. 2021 Mar 25:1-4. doi: 10.1080/14656566.2021.1904892. Online ahead of print.ABSTRACTIntroduction: Chronic kidney disease occurs in 40% of subjects with diabetes and increases the risk of cardiovascular death three-fold, compared to having diabetes alone. The non-steroidal mineralocorticoid receptor antagonist finerenone protects against chronic kidney disease in animal models.Areas covered: This evaluation is of a phase 3 trial of finerenone; Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD). In FIDELIO-DKD, finerenone reduced the primary composi...
Source: Expert Opinion on Pharmacotherapy - March 25, 2021 Category: Drugs & Pharmacology Authors: Sheila A Doggrell Source Type: research

Issues in Antibiotic Therapy for Hospital-Acquired and Ventilator-Associated Pneumonia: Emerging Concepts to Improve Outcomes
Expert Opin Pharmacother. 2021 Mar 25. doi: 10.1080/14656566.2021.1908997. Online ahead of print.ABSTRACTIntroductionVentilator-associated pneumonia (VAP) and hospital-acquired pneumonia (HAP) result in significant morbidity and mortality. The emergence of multi-drug resistant organisms has complicated the matter, as many of these pathogens now represent key causes of VAP and HAP. While a number of new medications have been approved, a comprehensive appreciation of pharmacokinetic and pharmacodynamic principles, which, are often neglected, is key to effective treatment.Areas coveredThe authors discuss the central pharmacok...
Source: Expert Opinion on Pharmacotherapy - March 25, 2021 Category: Drugs & Pharmacology Authors: Syed Nazeer Mahmood Andrew F Shorr Source Type: research

Finerenone - are we there yet with a non-steroidal mineralocorticoid receptor antagonist for the treatment of diabetic chronic kidney disease?
Expert Opin Pharmacother. 2021 Mar 25:1-4. doi: 10.1080/14656566.2021.1904892. Online ahead of print.ABSTRACTIntroduction: Chronic kidney disease occurs in 40% of subjects with diabetes and increases the risk of cardiovascular death three-fold, compared to having diabetes alone. The non-steroidal mineralocorticoid receptor antagonist finerenone protects against chronic kidney disease in animal models.Areas covered: This evaluation is of a phase 3 trial of finerenone; Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD). In FIDELIO-DKD, finerenone reduced the primary composi...
Source: Expert Opinion on Pharmacotherapy - March 25, 2021 Category: Drugs & Pharmacology Authors: Sheila A Doggrell Source Type: research

Issues in Antibiotic Therapy for Hospital-Acquired and Ventilator-Associated Pneumonia: Emerging Concepts to Improve Outcomes
Expert Opin Pharmacother. 2021 Mar 25. doi: 10.1080/14656566.2021.1908997. Online ahead of print.ABSTRACTIntroductionVentilator-associated pneumonia (VAP) and hospital-acquired pneumonia (HAP) result in significant morbidity and mortality. The emergence of multi-drug resistant organisms has complicated the matter, as many of these pathogens now represent key causes of VAP and HAP. While a number of new medications have been approved, a comprehensive appreciation of pharmacokinetic and pharmacodynamic principles, which, are often neglected, is key to effective treatment.Areas coveredThe authors discuss the central pharmacok...
Source: Expert Opinion on Pharmacotherapy - March 25, 2021 Category: Drugs & Pharmacology Authors: Syed Nazeer Mahmood Andrew F Shorr Source Type: research

Rethinking the use of hypnotics for treatment of insomnia in the elderly
Expert Opin Pharmacother. 2021 Mar 23:1-5. doi: 10.1080/14656566.2021.1900116. Online ahead of print.NO ABSTRACTPMID:33757383 | DOI:10.1080/14656566.2021.1900116 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - March 24, 2021 Category: Drugs & Pharmacology Authors: Dieter Kunz Source Type: research

Are current SGLT2 Inhibitors efficacious treatment options for Type 1 diabetes?
Expert Opin Pharmacother. 2021 Mar 23:1-3. doi: 10.1080/14656566.2021.1900824. Online ahead of print.NO ABSTRACTPMID:33754937 | DOI:10.1080/14656566.2021.1900824 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - March 23, 2021 Category: Drugs & Pharmacology Authors: Yoko Koike Yasuo Terauchi Source Type: research

Topical calcipotriol plus betamethasone dipropionate for the treatment of plaque psoriasis: a drug evaluation
Expert Opin Pharmacother. 2021 Mar 22:1-11. doi: 10.1080/14656566.2021.1900825. Online ahead of print.ABSTRACTIntroduction: Psoriasis is an inflammatory skin disease affecting approximately 3.2% of adults in the United States. The mainstay treatment for mild-to-moderate plaque psoriasis (the most common subtype and severity) is topical therapy.Areas covered:The fixed combination calcipotriol plus betamethasone dipropionate (BD) is an effective topical treatment for plaque psoriasis. Two therapies with separate actions - a Vitamin D analog and a high-potency topical corticosteroid - combined into a single medication allows ...
Source: Expert Opinion on Pharmacotherapy - March 22, 2021 Category: Drugs & Pharmacology Authors: Caitlin G Purvis Esther A Balogh Courtney E Heron Steven R Feldman Source Type: research

Current and Emerging Pharmacotherapy for Recurrent Bacterial Vaginosis
Expert Opin Pharmacother. 2021 Mar 22. doi: 10.1080/14656566.2021.1904890. Online ahead of print.ABSTRACTINTRODUCTION: : Given the frequency of bacterial vaginosis recurrences (RBV), enhancing treatment and preventing recurrence has become the central target of pharmacotherapy today. Antimicrobial failure is occurring at a time when knowledge of pathogenesis of BV and RBV is incomplete, limiting rational treatment modification.AREAS COVERED: : The current manuscript reviews pathogenesis of RBV and the performance of antimicrobials available as well as attempts employed to enhance activity and pharmacologic strategies to re...
Source: Expert Opinion on Pharmacotherapy - March 22, 2021 Category: Drugs & Pharmacology Authors: Jack D Sobel Ryan Sobel Source Type: research

Topical calcipotriol plus betamethasone dipropionate for the treatment of plaque psoriasis: a drug evaluation
Expert Opin Pharmacother. 2021 Mar 22:1-11. doi: 10.1080/14656566.2021.1900825. Online ahead of print.ABSTRACTIntroduction: Psoriasis is an inflammatory skin disease affecting approximately 3.2% of adults in the United States. The mainstay treatment for mild-to-moderate plaque psoriasis (the most common subtype and severity) is topical therapy.Areas covered:The fixed combination calcipotriol plus betamethasone dipropionate (BD) is an effective topical treatment for plaque psoriasis. Two therapies with separate actions - a Vitamin D analog and a high-potency topical corticosteroid - combined into a single medication allows ...
Source: Expert Opinion on Pharmacotherapy - March 22, 2021 Category: Drugs & Pharmacology Authors: Caitlin G Purvis Esther A Balogh Courtney E Heron Steven R Feldman Source Type: research

Does hydroxychloroquine still have any role in the COVID-19 pandemic?
Expert Opin Pharmacother. 2021 Mar 16:1-10. doi: 10.1080/14656566.2021.1898589. Online ahead of print.ABSTRACTIntroduction: The 4-aminoquinolines, chloroquine, and hydroxychloroquine have been used for over 70 years for malaria and rheumatological conditions, respectively. Their broad-spectrum antiviral activity, excellent safety profile, tolerability, low cost, and ready availability made them prime repurposing therapeutic candidates at the beginning of the COVID-19 pandemic.Areas covered: Here, the authors discuss the history of hydroxychloroquine and chloroquine, the in vitro data which led to their widespread repurposi...
Source: Expert Opinion on Pharmacotherapy - March 16, 2021 Category: Drugs & Pharmacology Authors: William Hk Schilling Nicholas J White Source Type: research

Current and emerging pharmacotherapy for Gaucher disease in pediatric populations
Expert Opin Pharmacother. 2021 Mar 12. doi: 10.1080/14656566.2021.1902989. Online ahead of print.ABSTRACTINTRODUCTION: The past decades have witnessed a remarkable improvement in the health of patients with Gaucher disease, the inherited deficiency of the lysosomal enzyme glucocerebrosidase, resulting from the availability of enzyme replacement and substrate reduction therapies. Especially in pediatric populations, early diagnosis and initiation of treatment is essential to achieving optimal outcomes.AREAS COVERED: The authors review the literature pertaining to the effectiveness of currently available therapies and descri...
Source: Expert Opinion on Pharmacotherapy - March 13, 2021 Category: Drugs & Pharmacology Authors: Richard Sam Emory Ryan Emily Daykin Ellen Sidransky Source Type: research

Desvenlafaxine in the treatment of major depression: an updated overview
Expert Opin Pharmacother. 2021 Mar 11. doi: 10.1080/14656566.2021.1900826. Online ahead of print.ABSTRACTIntroduction: Major depressive disorder (MDD) remains one of the most prevalent mental health conditions. It is a chronic, relapsing condition and despite multiple treatment options, many patients fail to achieve remission of symptoms. Inadequacy of treatment has stimulated the search for agents with significant therapeutic advantages.Areas covered: This review examines literature concerning the use of desvenlafaxine in the treatment of MDD published since a previous analysis in this journal in 2014. Published papers we...
Source: Expert Opinion on Pharmacotherapy - March 12, 2021 Category: Drugs & Pharmacology Authors: Trevor R Norman James S Olver Source Type: research

Novel synthetic drugs for the treatment of non-Hodgkin lymphoma
This article provides a comprehensive review of approved synthetic drugs targeting the BTK, PI3K, immunomodulation, proteasome, HDAC, EZH2, and nuclear export pathways in non-Hodgkin lymphoma. The review includes coverage of the pharmacology, efficacy, toxicity, and active areas of research for each drug. The authors also provide their expert perspectives on the field and their opinions for the future.Expert opinion: Although novel synthetic drugs have generally not impacted clinical practice to the same extent as immune and cellular therapies, there remains an important role for targeted drugs in the treatment of non-Hodg...
Source: Expert Opinion on Pharmacotherapy - March 12, 2021 Category: Drugs & Pharmacology Authors: Farheen Manji Robert Puckrin Douglas A Stewart Source Type: research